PositiveID announced this week that its cellular-enabled iGlucose mobile health system, which adds cellular connectivity to a handful of commercially available glucose meters, is now available for pre-order. It expects to commercially launch the device sometime during this quarter. The company also claimed to be in the process of rolling out pilot programs with health insurers and home-healthcare providers, but did not provide specifics.
In November 2011 PositiveID announced that the FDA had cleared iGlucose, which only worked with two glucose meters at the time: the LifeScan OneTouch and Nipro Diagnostic True. Now the device also works with Abbott FreeStyle and Bayer Contour devices too, according to the company. The iGlucose device transmits the data to a secure database via a cellular connection supported by AT&T in the US and Rogers in Canada.
“iGlucose eliminates the burden of keeping manual logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition,” according to a company press release. “iGlucose uses mobile technology to seamlessly communicate blood glucose readings from an individual’s data-capable glucometer to the iglucose diabetes management portal, where, with the user’s consent, glucose readings can be shared automatically with family members, caregivers and healthcare professionals via text message, email or fax.”
Last year Glooko started selling a cord that connects already available glucose meters to a user’s iPhone to transmit data to an app on the device — another way to solve the manual logbook issue. Telcare, the first cellular-enabled and integrated glucose meter, also recently became commercially available after securing an FDA clearance in August 2011. Sanofi and AgaMatrix’s iBGStar iPhone peripheral glucose meter is currently available in Europe but has yet to commercially launch in the US after securing FDA clearance late last year.
More on the imminent iGlucose launch in the press release below:
DELRAY BEACH, Fla., Apr 11, 2012 (GlobeNewswire via COMTEX) — PositiveID Corporation (“PositiveID” or “Company”) PSID +5.06% , an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America’s homeland defense, today announced it has begun taking orders of its FDA-cleared iglucose(R) mobile health system for diabetes management. Pre-orders are being accepted through the iglucose website at www.iglucose.com and the PositiveID website at www.positiveidcorp.com . PositiveID expects to commercially launch iglucose during the second quarter of 2012.
PositiveID’s FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating blood glucose readings from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals, making it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose does not require the use of a cell phone or a wireless plan.
“As we complete the final stages of preparing for the commercial launch of iglucose, we are pleased, based on consumer demand, to be able to provide the opportunity to pre-order this FDA-cleared system for diabetes management,” stated William J. Caragol, Chairman and CEO of PositiveID. “Those who order will be given priority status while we initially roll-out iglucose through pilot programs with health insurers and home-healthcare providers.”
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Bayer Contour (R), and Nipro Diagnostic(TM) True(TM) monitoring systems to a secure database via wireless cellular technology. The Company is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com .
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America’s homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com .